Novartis Clozaril
Executive Summary
Weekly blood monitoring requirement in labeling for clozapine has been modified to weekly testing for the first six months of therapy followed by biweekly testing for patients with acceptable white blood cell counts. FDA's Psychopharmacologic Drugs Advisory Committee recommended changing the monitoring schedule for the antipsychotic in July 1997. Clozaril has required monitoring since it came on the market because of a 1%-2% incidence of agranulocytosis...